Phase I study of docetaxel and topotecan in patients with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 6, 2000, Pages 442-448

  Tkaczuk, Katherine H ^a   Zamboni, William C ^b   Tait, Nancy S ^a   Meisenberg, Barry R ^a   Doyle, L Austin ^a   Edelman, Martin J ^a   Hausner, Petr F ^a   Egorin, Merrill J ^b   Van Echo, David A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Docetaxel; Phase I; Solid tumors; Topotecan

Indexed keywords

DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; MALE; MICROTUBULE ASSEMBLY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0033647495     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000180     Document Type: Article

References (43)

1. Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol
2. The clinical pharmacology and use of antimicrobutule agents in cancer therapeutics
3. Taxol: Mechanisms of action and resistance
4. Taxol: An antimitotic agent with a new mechanism of action
5. Bcl2 is the guardian of microtubule integrity
6. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits
7. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl2
8. Clinical pharmacokinetics of topotecan
9. Topotecan a novel topoisomerase inhibitor: Pharmacology and clinical experience
10. Pharmacokinetics and metabolism of Taxotere (docetaxel)
11. 14C radiolabelled docetaxel (RP 56976, NSC628503) in cancer patients
12. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
13. Pharmacokinetic and pharmacodynamic properties of docetaxel: Results of phase I and phase II trials
14. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
15. Pharmacokinetics of cisplatin and Taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence docetaxel/cisplatin and cisplatin/docetaxel in a phase I/II study in solid tumours
16. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study
17. Topotecan in the treatment of gynecologic cancer
18. Topoisomerase I inhibitors: Review and update
19. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion
20. Phase I study of docetaxel as a 1-hour infusion on a weekly basis
21. Docetaxel (Taxotere): An active drug for the treatment of advanced squamous cell carcinoma of the head and neck
22. A phase I study of topotecan hydrochloride (a topoisomerase I inhibitor) in combination with doxorubicin (a topoisomerase II inhibitor)
23. Phase I trial of lowdose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen
24. Taxotere (TXT) for advanced, incurable squamous cell carcinoma of the head and neck (SCCHN)
25. Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial
26. Phase II study of Taxotere (RP56976, docetaxel) in advanced pancreatic adenocarcinoma (PAC)
27. Docetaxel (Taxotere) in advanced malignant melanoma: A phase II study of the EORTC Early Clinical Trials Group
28. Phase II trial of Taxotere (RP56976) in patients (PTS) with metastatic melanoma previously untreated with cytotoxic chemotherapy
29. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group
30. Phase II study of docetaxel (Taxotere) in anthracycline refractory metastatic breast cancer (ARMBC)
31. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
32. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients
33. Limited sampling model for area under the concentration time curve of total topotecan
34. A population pharmacokinetic model for Taxotere (docetaxel): Model building and validation
35. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
36. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography
37. A new docetaxel solid-phase extraction procedure in human plasma for pharmacokinetics determination
38. High-performance liquid chromatographic determination of the novel antitumor drug topotecan as the total of the lactone plus carboxylate forms in human plasma
39. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan
40. Phase I study of paclitaxel and topotecan in patients with advanced tumors: A cancer and leukemia group B study